Antimicrobial peptide Halymorin variants and methods of using the same

USPTO published patent application US20260092082A1 on April 2, 2026, filed by Antinbio, Inc. (Application No. 18901435, filed September 30, 2024). The application discloses novel antimicrobial peptide Halymorin variants with amino acid sequences defined by SEQ ID NOs: 2-12. These peptides exhibit antimicrobial activity against multiple Gram-negative bacteria and specific pathogens including Campylobacter jejuni, Escherichia coli, Salmonella enterica (serovars Typhimurium and choleraesuis), Klebsiella pneumoniae, and Enterobacter cloacae. The broad claims encompass compositions for pharmaceutical, food additive, cosmetic, and hygiene product applications, as well as methods of treating infectious diseases using these peptides as active ingredients.\n\nCompetitors developing similar antimicrobial peptides or seeking to use Halymorin variants in therapeutic applications should evaluate freedom-to-operate considerations and potential licensing needs. No compliance deadlines or comment periods apply to this patent publication. The document is informational, describing the scope of intellectual property protection being sought rather than imposing regulatory obligations.